FDA approves Rasonque for metastatic pancreatic cancer treatment

The FDA has granted approval for Rasonque, a targeted therapy for metastatic pancreatic cancer that demonstrated nearly double the survival rates in clinical trials. The approval marks a significant therapeutic advancement for a condition with historically poor prognosis, though long-term real-world efficacy remains to be established.